Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Enovix's Q2 2025 earnings call highlights record revenue growth, A1 platform launch, and commercialization strides.

Timing factors contributed to a 17% year-over-year growth in Broadcast, an 11% decline in Mobile, and 22% growth in PC. Broadcast is expected to be flat for the full year, with mobile and other end ...

The schedule is arranged to enable a theatergoer to see all four productions in the  three days. The cost is $30.

The card network said inflation remains in check, any impacts of Capital One moving cards to the Discover network will be ...

Starbucks CEO Brian Niccol says his company will rebound from lackluster earnings with its “green apron service” plan. Here’s ...

FTI Consulting’s second quarter results drew a positive market response as the company delivered solid performance despite flat year-over-year sales and notable headwinds. Management cited ongoing ...

Mastercard boosted its guidance for the year, suggesting to one analyst that Visa’s forecast is “overly conservative.” ...

Sweetgreen, Inc. (NYSE:SG) is a fast-casual restaurant chain specializing in serving healthy, plant-forward food, primarily ...

Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...